Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients 56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50%...
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium – Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity...
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 – Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – –...
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) – Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity Investment from Johnson &...
Merck Completes Acquisition of Harpoon Therapeutics, Inc. Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager RAHWAY, N.J.–(BUSINESS...
Recent Comments